All In Biotech

Drug Trial Radar · NCT05033132

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer

Last checked: Nov 20, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 1, 2021

Primary completion

Dec 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
Collaborators
Betta Pharmaceuticals Co., Ltd.
First posted
Sep 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.

Conditions

  • Cervical Cancer

Interventions

  • BalstilimabDrug

    Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody

  • Balstilimab + ZalifrelimabDrug

    An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Of Balstilimab Monotherapy Per Independent Review Committee (IRC) Assessment Based Upon Response Evaluation Criteria In Solid Tumours (RECIST) 1.1Time frame: 36 months

Locations

43 sites in 1 country. Site status is shown where the registry gives one.

  • Betta Clinical Study Site 4

    Bengbu, Anhui, China

  • Betta Clinical Study Site 2

    Hefei, Anhui, China

  • Betta Clinical Study Site 3

    Hefei, Anhui, China

  • Betta Clinical Study Site 27

    Wuhu, Anhui, China

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Betta Clinical Study Site 25

    Beijing, Beijing Municipality, China

  • Betta Clinical Study Site 42

    Chongqing, Chongqing Municipality, China

  • Betta Clinical Study Site 9

    Fuzhou, Fujian, China

  • Betta Clinical Study Site 22

    Xiamen, Fujian, China

  • Betta Clinical Study Site 41

    Lanzhou, Gansu, China

  • Betta Clinical Study Site 39

    Lanzhou, Gansu, China

  • Betta Clinical Study Site 14

    Huizhou, Guangdong, China

  • Betta Clinical Study Site 18

    Meizhou, Guangdong, China

  • Betta Clinical Study Site 10

    Zhanjiang, Guangdong, China

  • Betta Clinical Study Site 11

    Nanning, Guangxi, China

  • Betta Clinical Study Site 5

    Cangzhou, Hebei, China

  • Betta Clinical Study Site 40

    Harbin, Heilongjiang, China

  • Betta Clinical Study Site 43

    Wuhan, Hubei, China

  • Betta Clinical Study Site 28

    Wuhan, Hubei, China

  • Betta Clinical Study Site 12

    Wuhan, Hubei, China

  • Betta Clinical Study Site 29

    Wuhan, Hubei, China

  • Betta Clinical Study Site 31

    Xiangyang, Hubei, China

  • Betta Clinical Study Site 6

    Changde, Hunan, China

  • Betta Clinical Study Site 36

    Changsha, Hunan, China

  • Betta Clinical Study Site 35

    Changsha, Hunan, China

  • Betta Clinical Study Site 13

    Changsha, Hunan, China

  • Betta Clinical Study Site 21

    Nanjing, Jiangsu, China

  • Betta Clinical Study Site 8

    Nanjing, Jiangsu, China

  • Betta Clinical Study Site 38

    Ganzhou, Jiangxi, China

  • Betta Clinical Study Site 19

    Nanchang, Jiangxi, China

  • Betta Clinical Study Site 20

    Nanchang, Jiangxi, China

  • Betta Clinical Study Site 24

    Shangrao, Jiangxi, China

  • Betta Clinical Study Site 16

    Changchun, Jilin, China

  • Betta Clinical Study Site 15

    Changchun, Jilin, China

  • Betta Clinical Study Site 7

    Dalian, Liaoning, China

  • Betta Clinical Study Site 34

    Shenyang, Liaoning, China

  • Betta Clinical Study Site 17

    Shenyang, Liaoning, China

  • Betta Clinical Study Site 30

    Xi'an, Shaanxi, China

  • Betta Clinical Study Site 23

    Taiyuan, Shanxi, China

  • Betta Clinical Study Site 26

    Tianjin, Tianjin Municipality, China

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.